Emma Cernis

Emma Cernis
Emma Cernis is a research assistant in the field of psychology. She has completed degrees in Experimental Psychology at the University of Oxford and Mental Health Studies at the Institute of Psychiatry, King's College London. Emma is an aspiring clinical psychologist and follows the development of anti-stigma campaigns with particular interest. On Twitter: @ECernis

Website

Follow me here –

Bullying and cyberbullying increase the risk of suicidal ideation and suicide attempts in adolescents

shutterstock_100019534

Bullying is just not good for you.  Here on Mental Elf, we’ve already picked some great examples of studies demonstrating this.  André blogged about how bullied children are more likely to develop psychosis, and how bullies are at higher risk for teen pregnancy, and not so long ago, I told you how Wolke et al demonstrated that [read the full story…]

Rates of psychosis in epilepsy may not be as high as previously reported, says new systematic review

cogs in outline of head

For many years, psychiatry has highlighted that people with epilepsy appear to have an elevated risk for psychosis.  However, studies exploring this relationship (of which there are many) seem to disagree on just what the prevalence of psychosis is in this group.  For example, Gudmundsson (1966) interviewed every patient with epilepsy in Iceland and concluded [read the full story…]

Bullying is bad for your mental health, even if you are the bully

shutterstock_114356416

Clinicians and mental health researchers have long recognised that there is a link between traumatic experiences in childhood and symptoms of psychosis or non-clinical psychotic experiences presenting in adolescence or adulthood. One type of traumatic experience is the experience of abuse, whether physical, emotional or social in nature.  When it comes to bullying, any or [read the full story…]

No evidence that behavioural therapies are any better than other psychological therapies for depression

Depression is a big problem.  In fact, it’s the third leading cause of disease burden worldwide (WHO, 2004 – as cited in Shinohara et al, 2013) and the largest source of nonfatal disease burden in the world (Ustun, 2004 – as cited in Shinohara et al, 2013).   What’s more, the number of people affected by it [read the full story…]

Cochrane review finds ‘solid’ evidence for CBT for anxiety in young people, but lacks evidence for long-term benefits

Anxiety disorders, such as generalised anxiety disorder (GAD), social anxiety, panic disorder and phobias, are common and affect between 5 – 19% of all children and adolescents (Costello, 2004; as cited in James et al, 2013, pg. 6).  Anxiety problems in childhood or adolescence can disrupt social and educational life, and may persist into adulthood. [read the full story…]

Vitamin D deficiency in psychosis: our current (limited) understanding according to the latest meta-analysis.

Get ready to amend your dopamine hypothesis and stop trying to wrap your neurons around the role of glutamate in the brain.  The rising star of the neurobiological schizophrenia literature is…. Vitamin D.  Yes, really. The more sceptical amongst you (including me) may feel that finding a vitamin deficiency in psychosis patients is perhaps not [read the full story…]

Cochrane review finds quetiapine is equivalent in efficacy to typical antipsychotics and possibly causes fewer side effects

Antipsychotic medication is the standard treatment for schizophrenia and psychosis in the UK.  Given that psychosis is commonly a chronic condition and therefore that medication used to treat it often needs to be taken for several years, getting the medication “right” is important. As I mentioned in my first blog post for the Mental Elf, [read the full story…]

Meta-analysis finds medium-sized deficit for IQ-change in schizophrenia patients

lightbulb brain

When Kraepelin first described the symptoms of the disorder we now call schizophrenia, he drew particular attention towards the deterioration of cognitive function he observed in his patients and named their condition “dementia praecox”. To this day, cognitive deficits are still regarded as one of the key features of schizophrenia (and related diagnoses), and it [read the full story…]

Cochrane review cannot support training to recognise early signs of recurrence in schizophrenia due to low quality evidence

man staring at piles of paper

NICE Guidelines state that around three quarters of people with a diagnosis of schizophrenia experience a chronic illness: with recurrent episodes of remission and relapse.  One way that chronic physical health conditions, such as diabetes and heart disease, are managed is by using early warning signs (EWS) training and this prevention strategy is now often [read the full story…]

German cohort study finds no support for superiority of atypical antipsychotics in schizophrenia

It is possible that those who were disengaging from interventions such as medication were less likely to take part in the study.

Schizophrenia according to the NICE guidelines, is a relatively common illness and in the majority of cases takes a chronic course, requiring continued management and careful attention.  In the treatment and management of schizophrenia, antipsychotic medications – like olanzapine, quetiapine or clozapine – are the first line intervention. Antipsychotics can be loosely divided into “first-generation” (“typical”) and [read the full story…]